One Chicago woman gave birth to twins 10 weeks prematurely, and the children needed extensive care. The medical bills topped out at around $80,000. Desperate, the parents loaded up credit cards, borrowed from relatives, and delayed repaying student loans.
People talk about the sacrifices they made when health care forced them into debt.
The U.S. health system now produces debt on a mass scale, a new investigation shows. Patients face gut-wrenching sacrifices.
Today, debt from medical and dental bills touches nearly every corner of American society.
Noble Health swept into two small Missouri towns promising to save their hospitals. Instead, workers and vendors say it stopped paying bills and government inspectors found it put patients at risk. Within two years — after taking millions in federal covid relief and big administrative fees — it locked the doors.
The U.S. House passed a package of bills seeking to keep some guns out of the hands of children and teenagers, but its fate in the Senate remains a big question mark. Meanwhile, the Federal Trade Commission takes on drug and hospital prices. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Cori Uccello of the American Academy of Actuaries about the most recent report from Medicare’s trustees board.
State Sen. Scott Wiener opens up about a weeklong stint in the hospital last year and what it’s like to live with Crohn’s disease. The San Francisco Democrat is pushing a bill that would require insurance companies to cover certain medications while patients appeal denials.
At a moment when half of U.S. states stand poised to outlaw or sharply curtail abortion services, the nation’s most popular emergency contraception brand rests in the unlikely stewardship of two private equity firms.
Gov. Gavin Newsom proposed spending $100 million to make insulin affordable to millions of people with diabetes under a new state generic drug label, CalRx. But state officials haven’t said how much the insulin will cost patients or how the state will deal with distribution and other challenges.
With its latest venture into primary care clinics, is America’s leading organization for seniors selling its trusted seal of approval?
